

Qalsody (tofersen)

Disclaimer

Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.

Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.

Qalsody (tofersen)	1
Summary	2
Definitions	2
Policy Statement on Qalsody (tofersen) Efficacy Information	3
Clinical Indications	6
Medical Necessity Criteria for Clinical Review	6
Indication-Specific Criteria	6
Amyotrophic Lateral Sclerosis (ALS) with a Superoxide Dismutase 1 (SOD1) Mutation	6
Experimental or Investigational or Unproven / Not Medically Necessary	6
Applicable Billing Codes	6
References	7
Clinical Guideline Revision / History Information	9

Summary

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron death, resulting in muscle weakness, paralysis, and eventual respiratory failure. Qalsody (tofersen) is an antisense oligonucleotide therapy specifically designed for ALS caused by mutations in the superoxide dismutase 1 (SOD1) gene. It aims to slow disease progression by reducing toxic SOD1 protein production.

Qalsody (tofersen) received accelerated approval from the FDA based on its ability to reduce plasma neurofilament light chain (NfL), a biomarker of neurodegeneration. However, confirmatory trials, such as the ongoing ATLAS study, are required to establish its clinical benefit. The VALOR trial, a pivotal Phase III study, did not demonstrate statistically significant improvements in clinical outcomes, such as ALS Functional Rating Scale-Revised (ALSFRS-R) scores, in the primary or secondary endpoints. Exploratory analyses from the open-label extension study suggest potential trends toward improved outcomes with earlier treatment, but these findings are not conclusive.

- Common adverse events associated with tofersen include procedural pain, headache, and lumbar puncture-related complications. Serious adverse events, such as myelitis, radiculitis, papilledema, and aseptic meningitis, have also been reported.

While tofersen offers a novel approach by targeting the genetic cause of ALS in SOD1 mutation patients, its clinical efficacy and long-term safety remain uncertain. Further evidence is needed to determine its role in ALS treatment.

Definitions

“Adverse events (AEs)” are unfavorable signs, symptoms, or diseases that occur during the course of treatment with a medication or intervention.

“Amyotrophic lateral sclerosis (ALS)” is a progressive neurodegenerative disease characterized by the death of motor neurons in the brain and spinal cord, resulting in muscle weakness, loss of motor function, and eventual paralysis.

“Amyotrophic Lateral Sclerosis Functional Rating Scale–Revised (ALSFRS-R)” is a tool used to assess functional abilities in patients with ALS, measuring four domains: breathing, bulbar, gross motor, and fine motor. Higher scores indicate better function.

“Cerebrospinal fluid (CSF)” is the fluid that surrounds the brain and spinal cord, which can be used to measure biomarkers and assess disease progression in ALS.

“Confirmatory trials” refers to additional clinical trials conducted to validate or confirm the results of previous studies, typically designed to replicate findings and further establish the clinical benefit and safety profile of a treatment.

“Efficacy information” refers to data that demonstrates the effectiveness or therapeutic benefits of a medication or intervention in treating a specific condition.

“Long-term outcomes” refers to the effects, benefits, or adverse events observed over an extended period of time, usually beyond the duration of a clinical trial, providing insights into the sustained efficacy and safety of a treatment.

“Open-label extension study” is a continuation of a clinical trial where patients who completed the original trial are offered the study drug or treatment under open-label conditions.

“Robust evidence” means strong, reliable, and conclusive evidence derived from well-designed and well-conducted clinical studies, often including randomized controlled trials, systematic reviews, and meta-analyses.

“Secondary endpoints” refers to additional outcome measures in a clinical trial that are evaluated to provide supplementary information beyond the primary endpoint, assessing different aspects of treatment efficacy or safety.

“Statistically significant” is a term used to describe results that are unlikely to have occurred by chance and are considered meaningful from a statistical perspective.

“[s]” indicates state mandates may apply.

[Policy Statement on Qalsody \(tofersen\) Efficacy Information^{\[s\]}](#)

The use of Qalsody (tofersen) is considered unproven and therefore not medically necessary for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD1 mutations or any other indication. While Qalsody has received FDA accelerated approval based on its ability to reduce plasma neurofilament light chain (NfL), a biomarker of neurodegeneration, the available clinical evidence does not demonstrate that it provides clinically meaningful benefits in terms of improving functional outcomes or slowing disease progression.

- Clinical trials:
 - The VALOR trial (n=108) and its open-label extension study (n=95) did not demonstrate statistically significant improvements in clinically meaningful outcomes, such as ALS Functional Rating Scale-Revised (ALSFRS-R) scores or other secondary endpoints. While reductions in biomarkers such as plasma NfL and cerebrospinal fluid (CSF) SOD1 protein were observed, these biomarkers have not been validated as surrogate endpoints for clinical benefit in ALS.
 - A long-term open-label extension of the VALOR study, 95/108 participants (88% of the original VALOR study participants) were enrolled and 46 participants completed the

extension trial. At 148 weeks, it was found that those who initiated Qalsody (tofersen) earlier vs. later/received placebo experienced less decline in their clinical function using the ALSFRS-R scores, respiratory function, muscle strength and quality of life. However, the study was limited by its small participants, and the fact that all participants were able to receive Qalsody (tofersen) for up to 2.5 years - none of the clinical outcomes were powered to detect a statistically significant difference between treatment groups.

- Qalsody received accelerated approval based on biomarker reductions, with continued approval contingent upon verification of clinical benefit in confirmatory trials. The ongoing ATLAS study and other trials are required to establish its clinical utility.
 - A 2025 systematic review and meta-analysis found that Qalsody (tofersen) significantly lowered the rate of decline in the ALSFRS-R scores from baseline compared to placebo (SMD = 0.44, 95% CI [0.05-0.83], p=0.03) and predicted Slow Vital Capacity (p=0.005). Qalsody (tofersen) also reduced SOD1 levels in CSF and NfL in plasma, consistent with the pivotal trial. This study consisted of 2 randomized controlled trials (RCTs) that were VALOR and a phase 1-2 dose study, 5 cohort studies, 1 case series, and 4 case reports. The small sample size (N=195), majority of studies included were in Germany, use of biomarkers, limit of one phase 3 RCT which did not find statistical significance (i.e., VALOR), high volume of observational studies, lack of control groups contribute to the low quality of this review and limit the generalizability of the findings. Additionally, a pre-post meta-analysis of five of the studies compared the ALS progression rate before and after treatment with Qalsody using mean difference. A pre-post meta-analysis is not considered reliable due to the effect of confounding factors resulting in biased outcomes and should be avoided in meta-analyses.
 - A case study of eleven patients (of which three received Qalsody [tofersen]) with facial-onset SOD1 ALS found inconsistent results with Qalsody (tofersen).
 - A 2025 real-world study suggests that Qalsody (tofersen) sustained declines in serum NfL and CSF phosphorylated neurofilament heavy chain (pNFH), disease stabilization as assessed by the ALSFRS-R total score, and improvement in functional independence measured by the functional independence measure (FIM) motor score. ALSFRS-R is a standard outcome measure rating instrument for monitoring the progression of disability in patients with ALS. While improvement in function was observed, this study was descriptive in nature and enrolled a small sample size of 7 patients. The expected ALSFRS-R used as a potential means of predicting how a patient would have done without Qalsody (tofersen) treatment is not an accepted measure thus using it to estimate disease progression is inexact. Additionally, the study was not powered or analyzed statistically; therefore, the magnitude of benefit against placebo continues to be unknown. The study notes that preservation of function and disease stabilization did not change quality of life as assessed by the ALS Assessment Questionnaire 5-Item Form (ALSAQ-5). Due to these concerns, this study limits the generalizability of the findings and contributes to the low quality of this study.
- On-going studies include:

- A clinical trial assessing Qalsody (tofersen) 100 mg for 24 weeks to assess NfL in the blood and CSF, safety and tolerability and quality of life in those with non-SOD1 ALS (NCT07294144, recruiting).
- A multi-center, open-label, postmarketing surveillance study of Qalsody (tofersen) evaluating the safety and pharmacokinetics in those with SOD1-ALS (NCT07223723, recruiting).
- An observational registry-based study evaluating the long-term safety (serious adverse effects, new comorbid conditions, treatment discontinuation) of Qalsody (tofersen) in those with SOD1-ALS (NCT07259980, not yet recruiting).
- A phase 3 randomized, placebo-controlled trial and open label extension assessing the efficacy, safety and tolerability of Qalsody (tofersen) versus placebo on presymptomatic adult carriers of SOD1 with elevated NfL (NCT04856982, active, not recruiting).
- Safety Considerations:
 - Serious adverse events, including myelitis, radiculitis, papilledema, and aseptic meningitis, have been reported in clinical trials. These safety concerns, combined with the lack of clear clinical efficacy, raise questions about the overall risk-benefit profile of Qalsody.
 - In the VALOR and VALOR open-label extension trial, almost 84% of those who took the study drug experienced an event related to the lumbar puncture, and almost 64% experienced an adverse event related to the study drug (21.2% of events had a fatal outcomes). The most common adverse effects were: headache, procedural pain, falls, back pain, pain in extremities, arthralgia, fatigue, CSF protein increase, post-lumbar puncture syndrome, nausea and constipation. The most common serious events included respiratory failure (12.5%) and pneumonia aspiration (11.5%).
 - A systematic review of the adverse effect profile of Qalsody (tofersen) found the most common side effects included pain related to repeated lumbar punctures (56.2%), headaches (54.1%), and pleocytosis (an increase in white blood cells in the CSF, 44.1%).
- Guideline/Position Statements:
 - The ALS Association supports the use of, and accelerated approval of Qalsody (tofersen) for those with SOD1-ALS, given it is an ultra-rare classification and aggressive form of ALS. They note that while the 28-week original VALOR study did not meet its primary endpoint, the clinical implications of reduced SOD1 protein levels in the CSF and reduced NfL indicate “a substantial reduction in the rate of degeneration.” They further cite the open label extension trial as proof of long-term clinical benefit (despite aforementioned limitations of the study).
 - Qalsody (tofersen) was approved by the European Union in 2024 under the accelerated approval pathway.
 - The European Academy of Neurology (EAN) guideline on the management of ALS in collaboration with the European Reference Network recommends Qalsody (tofersen) as first-line for the management of SOD1-ALS.

- TRICALS (Treatment Research initiative to Cure ALS), a European research initiative, released a formal consensus statement in 2023, stating the following: “The consensus view of TRICALS neurologists is that Tofersen shows clear benefit for people with ALS due to SOD1 mutation, especially if given early in the disease course, and support should be given for licensing in this group of patients.”
- There are no current US-based guidelines which cite support for Qalsody (tofersen) for those with SOD1-ALS at this time.

Clinical Indications

Medical Necessity Criteria for Clinical Review^[s]

Indication-Specific Criteria

Amyotrophic Lateral Sclerosis (ALS) with a Superoxide Dismutase 1 (SOD1) Mutation

Due to the uncertain clinical evidence, the Plan does not have standard medical necessity criteria for Qalsody (tofersen) at this time. Coverage for Qalsody (tofersen) for members with confirmed SOD1-mutated ALS will be determined on a case-by-case basis.

Experimental or Investigational or Unproven / Not Medically Necessary^[s]

Qalsody (tofersen) for any indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, unproven, or not medically necessary. The Plan has determined that the available evidence does not support the clinical efficacy, safety, or medical necessity of Qalsody at this time.

The Plan will continue to monitor emerging evidence, including results from ongoing clinical trials, and will reassess its position as new data become available. Until then, alternative treatment options with established efficacy and safety profiles, such as riluzole and edaravone, should be considered in consultation with healthcare providers.

Applicable Billing Codes

Table 1	
CPT/HCPCS Codes considered experimental, investigational, unproven, or not medically necessary:	
<i>Code</i>	<i>Description</i>
62322	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); without imaging guidance

Table 1	
CPT/HCPCS Codes considered experimental, investigational, unproven, or not medically necessary:	
<i>Code</i>	<i>Description</i>
62323	Injection(s), of diagnostic or therapeutic substance(s) (eg, anesthetic, antispasmodic, opioid, steroid, other solution), not including neurolytic substances, including needle or catheter placement, interlaminar epidural or subarachnoid, lumbar or sacral (caudal); with imaging guidance (ie, fluoroscopy or CT)
J1304	Injection, tofersen, 1 mg

Table 2	
ICD-10 codes considered experimental, investigational, unproven, or not medically necessary with Table 1 (CPT/HCPCS) codes:	
<i>Code</i>	<i>Description</i>
G12.21	Amyotrophic lateral sclerosis
G12.23	Primary lateral sclerosis

References

1. ALS Association. ALS Association Submits Comments in FDA Review of Tofersen. Available at: <https://www.als.org/stories-news/als-association-submits-public-comments-fda-review-tofersen#:~:text=Knowing%20the%20urgent%20need%20for,a%20surrogate%20marker%20that%20is.> Accessed 18 March 2026.
2. Benatar M, Wu J, Andersen PM, et al. Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. *Neurotherapeutics*. Epub ahead of print. May 18, 2022;10.1007/s13311-022-01237-4. doi:10.1007/s13311-022-01237-4
3. Berdyński M, Miszta P, Safranow K, et al. SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity. *Sci Rep*. 2022;12(1):103. doi:10.1038/s41598-021-03891-8
4. Brown CA, Lally C, Kupelian V, Flanders WD. Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants. *Neuroepidemiology*. 2021;55(5):342-353. doi:10.1159/000516752
5. Cuijpers P, Weitz E, Cristea IA, Twisk J. Pre-post effect sizes should be avoided in meta-analyses. *Epidemiol Psychiatr Sci*. 2017 Aug;26(4):364-368.
6. Everett WH, Bucelli RC. Tofersen for SOD1 ALS. *Neurodegener Dis Manag*. 2024;14(5):149-160. doi: 10.1080/17582024.2024.2402216. Epub 2024 Sep 27.
7. Hamad AA, Alkhaldeh IM, Nashwan AJ, Meshref M, Imam Y. Tofersen for SOD1 amyotrophic lateral sclerosis: a systematic review and meta-analysis. *Neurol Sci*. 2025 May;46(5):1977-1985.
8. Huai J, Zhang Z: Structural Properties and Interaction Partners of Familial ALS-Associated SOD1 Mutants. *Front Neurol*. 2019 May 21;10:527. doi: 10.3389/fneur.2019.00527.

9. Milella G, Carlone S, Luisi F, Velucci V, Defazio G. Facial-onset SOD1 amyotrophic lateral sclerosis: A case report and systematic review. *J Clin Neurosci.* 2026 Mar;145:111856. doi: 10.1016/j.jocn.2026.111856. Epub 2026 Jan 10.
10. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology.* 2009; 73:1218.
11. Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. *N Engl J Med.* 2020;383(2):109-119. doi:10.1056/NEJMoa2003715
12. Miller TM, Cudkowicz ME, Genge A, et al; VALOR and OLE Working Group. Trial of antisense oligonucleotide tofersen for SOD1 ALS. *N Engl J Med.* 2022;387(12):1099-1110. doi:10.1056/NEJMoa2204705
13. Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. *N Engl J Med.* 2022;387(12):1099-1110. doi:10.1056/NEJMoa2204705.
14. Miller TM, Cudkowicz ME, Shaw PJ, et al. Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis. *JAMA Neurol.* 2026 Feb 1;83(2):115-125. doi: 10.1001/jamaneurol.2025.4946.
15. Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study [published correction appears in *Lancet Neurol.* May 2013;12(5):423]. *Lancet Neurol.* 2013;12(5):435-42. doi:10.1016/S1474-4422(13)70061-9.
16. Qalsody (tofersen) [prescribing information]. Cambridge, MA: Biogen MA Inc; April 2023.
17. Moriyama H, Yokota T. Recent Progress of Antisense Oligonucleotide Therapy for Superoxide-Dismutase-1-Mutated Amyotrophic Lateral Sclerosis: Focus on Tofersen. *Genes (Basel).* 2024 Oct 20;15(10):1342. doi: 10.3390/genes15101342. PMID: 39457466; PMCID: PMC11507444.
18. Oliveira Santos M, de Carvalho M. Profiling tofersen as a treatment of superoxide dismutase 1 amyotrophic lateral sclerosis. *Expert Rev Neurother.* 2024 Jun;24(6):549-553. doi: 10.1080/14737175.2024.2355983. Epub 2024 May 17. PMID: 38758193.
19. Sabatelli M, Cerri F, Zuccarino R, et al. Long-term treatment of SOD1 ALS with tofersen: a multicentre experience in 17 patients. *J Neurol.* 2024 Aug;271(8):5177-5186. doi: 10.1007/s00415-024-12437-7. Epub 2024 Jun 3.
20. Shoesmith C, Abrahao A, Benstead T, et al. Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. *CMAJ.* 2020 Nov 16;192(46):E1453-E1468. doi: 10.1503/cmaj.191721.
21. Siddique N, Siddique T. Amyotrophic Lateral Sclerosis Overview. 2001 Mar 23 [Updated 2023 Sep 28]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. *GeneReviews®* [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1450/>.
22. Smith SE, McCoy-Gross K, Malcolm A, Oranski J, Markway JW, Miller TM, Bucelli RC. Tofersen treatment leads to sustained stabilization of disease in SOD1 ALS in a "real-world" setting. *Ann Clin Transl Neurol.* 2025 Feb;12(2):311-319.
23. Tarazona-Santabalbina FJ, Belenguer-Varea A, Borrás-Blasco J, et al. Safety profile of tofersen in amyotrophic lateral sclerosis: a systematic review and meta-analysis. *Neurol Sci.* 2026 Feb 26;47(3):292. doi: 10.1007/s10072-025-08793-5.
24. TRICALS. TRICALS consensus statement on Tofersen. Mar 7, 2023. Available at: <https://www.tricals.org/news/tricals-consensus-statement-on-tofersen>. Accessed March 19, 2026.
25. Van Damme P, Al-Chalabi A, Andersen PM, et al. European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD). *Eur J Neurol.* 2024 Jun;31(6):e16264.

Clinical Guideline Revision / History Information

Original Date: 06/29/2023

Reviewed/Revised: 10/27/2023, 12/19/2024, 11/01/2025, 06/01/2026